[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353644":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":37,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":10,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients treated with CLET",null,"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through \"drugs-in-special-situation\" request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Margarita Calonge, MD, PhD","CONTACT","34983184750","calonge@ioba.med.uva.es",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"IOBA","Valladolid","47011","Spain","ES",{"type":26,"coordinates":27},"Point",[28,29],-4.72353,41.65541,{"lat":29,"lon":28},[32,33],{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"name":14,"role":34,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[38,41,43],{"name":39,"class":40},"Citospin","INDUSTRY",{"name":42,"class":40},"Red de Terapia Celular",{"name":44,"class":6},"University of Valladolid","100353644","cultivated-limbal-epithelial-transplantation-clet-for-limbal-stem-cell-deficiency-lscd-100353644",false,"NCT03884569","Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD)","Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD): an Observational Study on Safety and Effectiveness","CLET-4-LSCD","Total and\u002For severe LSCD of any etiology in one or both eyes.","ALL",{"count":55,"type":56},30,"ESTIMATED","OBSERVATIONAL","CLET is a published treatment for the management of corneal failure due to extensive LSCD. Due to our previous studies on this novel treatment, the regulatory agency of Spain \"Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)\" authorized our institution (IOBA-University of Valladolid) to perform this kind of therapy (CLET) in a case-by-case base following the Special Situation Medicines Policy Procedure in Spain. Upon approval of the permanent authorization patients will be included as specified by AEMPS.The objective of this study is to perform a protocolized treatment and follow up so that results can be reported to the scientific community.",[60],"Limbal Stem-cell Deficiency",[62,63,64,65,66],"limbal stem cell deficiency","corneal failure","limbal epithelial stem cells","ocular surface","corneal blindness","NOT_YET_RECRUITING","2025-05-14",{"date":70,"type":71},"2025-05-16","ACTUAL",{"date":73,"type":56},"2025-11",{"date":75,"type":56},"2025-12-31",{"name":5,"class":6},1]